Spectral AI FY2024 EPS Estimate Boosted by Northland Capmk

Spectral AI, Inc. (NASDAQ:MDAI) – Equities research analysts at Northland Capmk boosted their FY2024 earnings per share estimates for shares of Spectral AI in a research note issued on Tuesday, December 3rd. Northland Capmk analyst C. Byrnes now anticipates that the company will earn ($0.48) per share for the year, up from their previous forecast of ($0.67). Northland Capmk currently has a “Strong-Buy” rating on the stock. The consensus estimate for Spectral AI’s current full-year earnings is ($0.54) per share. Northland Capmk also issued estimates for Spectral AI’s Q4 2024 earnings at ($0.10) EPS.

Several other equities research analysts have also recently issued reports on the company. Northland Securities started coverage on Spectral AI in a report on Monday, August 12th. They issued an “outperform” rating and a $6.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $3.50 price objective on shares of Spectral AI in a report on Tuesday, August 13th.

Spectral AI Stock Down 6.5 %

NASDAQ MDAI opened at $2.03 on Thursday. Spectral AI has a 52 week low of $0.82 and a 52 week high of $3.72. The firm has a market capitalization of $37.74 million, a P/E ratio of -3.12 and a beta of 0.64. The company has a 50-day moving average price of $1.37 and a 200-day moving average price of $1.51.

Hedge Funds Weigh In On Spectral AI

A hedge fund recently bought a new stake in Spectral AI stock. Forum Financial Management LP acquired a new stake in Spectral AI, Inc. (NASDAQ:MDAI) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 29,098 shares of the company’s stock, valued at approximately $51,000. Forum Financial Management LP owned approximately 0.17% of Spectral AI as of its most recent SEC filing. 67.08% of the stock is currently owned by institutional investors.

About Spectral AI

Spectral AI, Inc, an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers.